This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Randomized Controlled Trial

. 2007 Nov;72(9):1164-5.

doi: 10.1038/sj.ki.5002511.

Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney

L Tylicki, P Rutkowski, M Renke, B Rutkowski

PMID: 17943159
DOI: 10.1038/sj.ki.5002511

Free article

Randomized Controlled Trial

Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney

L Tylicki et al. Kidney Int. 2007 Nov.

Free article

. 2007 Nov;72(9):1164-5.

doi: 10.1038/sj.ki.5002511.

Authors

L Tylicki, P Rutkowski, M Renke, B Rutkowski

PMID: 17943159
DOI: 10.1038/sj.ki.5002511

No abstract available

PubMed Disclaimer

Comment on

Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.
Kramer AB, van der Meulen EF, Hamming I, van Goor H, Navis G. Kramer AB, et al. Kidney Int. 2007 Mar;71(5):417-24. doi: 10.1038/sj.ki.5002075. Epub 2007 Jan 10. Kidney Int. 2007. PMID: 17213874

Similar articles

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Tylicki L, et al. Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18. Am J Kidney Dis. 2008. PMID: 18423812 Clinical Trial.
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M, Danser AH, Menard J, Waeber B, Mueller DN, Maggioni AP, Ruilope LM. Volpe M, et al. J Hypertens. 2012 Apr;30(4):647-54. doi: 10.1097/HJH.0b013e32834f6e00. J Hypertens. 2012. PMID: 22278139 Review.
Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T. Furumatsu Y, et al. Hypertens Res. 2008 Jan;31(1):59-67. doi: 10.1291/hypres.31.59. Hypertens Res. 2008. PMID: 18360019 Clinical Trial.
Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Sato A, Saruta T, Funder JW. Sato A, et al. Hypertens Res. 2006 Apr;29(4):211-6. doi: 10.1291/hypres.29.211. Hypertens Res. 2006. PMID: 16778327 Review.
Preventing renal disease progression: can complete renin-angiotensin-aldosterone blockade work?
Schreiber MJ Jr. Schreiber MJ Jr. Cleve Clin J Med. 2008 Oct;75(10):699-700, 703-4. doi: 10.3949/ccjm.75.10.699. Cleve Clin J Med. 2008. PMID: 18939385 No abstract available.

See all similar articles

Cited by

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Navaneethan SD, et al. Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908. Epub 2009 Mar 4. Clin J Am Soc Nephrol. 2009. PMID: 19261819 Free PMC article.
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G. Waanders F, et al. Am J Kidney Dis. 2009 Jan;53(1):16-25. doi: 10.1053/j.ajkd.2008.07.021. Epub 2008 Sep 27. Am J Kidney Dis. 2009. PMID: 18823687 Free PMC article. Clinical Trial.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Cooper TE, et al. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3. Cochrane Database Syst Rev. 2023. PMID: 37466151 Free PMC article.
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Chung EY, et al. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4. Cochrane Database Syst Rev. 2020. PMID: 33107592 Free PMC article.
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Lytvyn Y, et al. Curr Diab Rep. 2019 Jan 23;19(1):4. doi: 10.1007/s11892-019-1123-8. Curr Diab Rep. 2019. PMID: 30673886 Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science